Understanding how some bacteria resist antibiotics
Heteroresistance Interdisciplinary Research Unit (Project 2)
This study is looking into how some bacteria, like Acinetobacter baumannii, can survive antibiotics while others can't, specifically focusing on the antibiotic fosfomycin, to help find better ways to treat infections caused by antibiotic-resistant bacteria.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11037954 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind antibiotic resistance, particularly focusing on a phenomenon called heteroresistance, where some bacteria can survive antibiotic treatment while others cannot. The study aims to explore how certain bacteria, like Acinetobacter baumannii, develop resistance to the antibiotic fosfomycin, which is increasingly used to treat infections. By understanding these resistance mechanisms, the research seeks to inform the development of new treatments and strategies to combat antibiotic-resistant infections, which pose a significant threat to patient health.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals suffering from infections caused by antibiotic-resistant bacteria, particularly those involving Acinetobacter baumannii.
Not a fit: Patients with infections that are not caused by antibiotic-resistant bacteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for antibiotic-resistant infections, improving patient outcomes and safety.
How similar studies have performed: Other research has shown promising results in understanding antibiotic resistance mechanisms, making this approach both relevant and necessary in the fight against resistant infections.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Weiss, David S — Emory University
- Study coordinator: Weiss, David S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.